PET Imaging of Prostate Cancer Using 11C-Acetate

PET Clinics

Volumn 4, Issue 2, 2009, Pages 163-172

  Czernin, Johannes ^a   Benz, Matthias R ^a   Allen Auerbach, Martin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

11C Acetate; Bio distribution; Detection; Pathways; PET; Pharmacokinetics; Prostate cancer; Protocols

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; FATTY ACID SYNTHASE; FLUOROACETIC ACID F 18; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; EARLY DIAGNOSIS; FATTY ACID METABOLISM; GENE EXPRESSION; GENE FUNCTION; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 68949189295     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.05.001     Document Type: Review

References (45)

1. Warburg O., Posener K., and Negelein E. The metabolism of cancer cells. Biochem Zeitschr 152 (1924) 129-169
2. Plathow C., and Weber W. Tumor cell metabolism imaging. J Nucl Med 49 Suppl 2 (2008) 43S-63S
3. Crupp M., and Oesterling J. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer. Mayo Clin Proc 68 (1993) 297-306
4. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
5. Cox J., Gallagher M., Hammond E., et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17 (1999) 1155-1163
6. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 11 (2004) 1325-1332
7. Leibman B., Dillioglugil O., Wheeler T., et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 76 (1995) 2530-2534
8. Partin A., and Oesterling J. The clinical usefulness of prostate specific antigen: update 1994. J Urol 152 (1994) 1358-1368
9. Heesakkers R.A., Hövels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9 9 (2008) 850-856
10. Hillner B., Siegel B., Shields A., et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115 (2009) 410-418
11. Hillner B.E., Liu D., Coleman R.E., et al. The national oncologic PET registry (NOPR): design and analysis plan. J Nucl Med 48 11 (2007) 1901-1908
12. Hillner B.E., Siegel B.A., Liu D., et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26 13 (2008) 2155-2161
13. Seltzer M., Barbaric Z., Belldegrun A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162 (1999) 1322-1328
14. Israel O., Goldberg A., Nachtigal A., et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging 33 11 (2006) 1280-1284
15. Chen Y., Sawyers C., and Scher H. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8 4 (2008) 440-448
16. Larson S., and Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 18 (2008) 65-70
17. Knowles L.M., Yang C., Osterman A., et al. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 283 46 (2008) 31378-31384
18. Waniewski R.A., and Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci 18 14 (1998) 5225-5233
19. Brown M., Marshall D.R., Sobel B.E., et al. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 76 3 (1987) 687-696
20. 11C]acetate and dynamic positron emission tomography. Circulation 79 (1989) 134-142
21. Buxton D.B., Schwaiger M., Nguyen A., et al. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res 63 3 (1988) 628-634
22. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66 (2006) 5977-5980
23. Baron A., Migita T., Tang D., et al. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 91 (2003) 47-53
24. Epstein J., Carmichael M., and Partin A. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45 (1995) 81-86
25. Swinnen J., Van Veldhoven P., Timmermans L., et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302 4 (2003) 898-903
26. Brusselmans K., De Schrijver E., Verhoeven G., et al. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65 (2005) 6719-6725
27. 11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49 (2008) 327-334
28. Beckers A., Organe S., Timmermans L., et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 67 (2007) 8180-8187
29. 18F]FDG in cultured prostate cancer cells. Nucl Med Biol 33 8 (2006) 977-984
30. 11C-acetate. J Nucl Med 48 (2007) 420-428
31. 11C-acetate whole-body PET. J Nucl Med 45 (2004) 1233-1236
32. 11C-acetate kinetics of prostate cancer. J Nucl Med 49 2 (2008) 206-215
33. Yoshimoto M., Waki A., Yonekura Y., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28 2 (2001) 117-122
34. 11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29 11 (2002) 1492-1495
35. Pound C., Partin A., Eisenberger M., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
36. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 4 (2003) 607-611
37. Kotzerke J., Volkmer B., Neumaier B., et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29 10 (2002) 1380-1384
38. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34 2 (2007) 185-196
39. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
40. Reske S., Blumstein N., and Glatting G. PET und PET/CT in der Rezidivdiagnostik des Prostatakarzinoms [PET and PET/CT in relapsing prostate carcinoma]. Urologe A 45 10 (2006) 1240-1250 [in German]
41. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 (2007) 1415-1420
42. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 24 (2006) 2513-2519
43. Sandblom G., Sörensen J., Lundin N., et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67 5 (2006) 996-1000
44. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 (2003) 25-30
45. Zhou W., Han W., and Landree L. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67 (2007) 2964-2971